Presight Sensei

Sensei Biotherapeutics is a clinical-stage biotech company developing next-generation immunotherapies for cancer, primarily focused on tumor microenvironment-activated antibodies and personalized phage-based therapies. Its lead candidate, solnerstotug (SNS-101), is a pH-selective monoclonal antibody targeting VISTA, designed to be active only in the acidic tumor microenvironment. Preclinical data show that solnerstotug enhances anti-PD-1 therapy, increasing tumor-infiltrating CD8 T cells and promoting a pro-inflammatory, anti-tumor state. The company expects to report Phase 1/2 clinical data in 2025 and, if additional funding is secured, initiate a Phase 2 trial in Q1 2026. Sensei has paused development of its preclinical candidates to focus resources on solnerstotug and recently reduced its workforce by 46%[1][3].